Novo Nordisk's HD Wegovy Challenges Zepbound in Weight Loss Race
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Novo Nordisk unveils HD Wegovy, a higher-dose version of its weight-loss drug, aiming to rival Eli Lillys Zepbound. While HD Wegovy shows promising results, it still lags behind Zepbound in weight loss and additional benefits like treating obstructive sleep apnea. Novos pipeline drugs, Amycretin and UBT251, hold potential for future growth. Despite recent setbacks, Novos stock remains undervalued, positioning it for long-term gains.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/a6f4654990fcc07f